Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, vol.38, pp.140-149, 2015. ,
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers, J Clin Endocrinol Metab, vol.87, pp.1239-1285, 2002. ,
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits, Diabetes Care, vol.33, pp.428-461, 2010. ,
Incretinbased therapies: viewpoints on the way to consensus, Diabetes Care, vol.32, issue.2, 2009. ,
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: A systematic review and meta-analysis, JAMA, vol.319, pp.1580-91, 2018. ,
Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas, Gastroenterology, vol.136, pp.1134-1178, 2009. ,
Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis, Gastroenterology, vol.133, pp.244-55, 2007. ,
Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues, Mol Biol Rep, vol.41, pp.4313-4333, 2014. ,
Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis, Gut, vol.58, pp.990-997, 2009. ,
LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med, vol.375, pp.311-333, 2016. ,
SAVOR-TIMI 53 Steering Committee and Investigators. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial, Diabetes Obes Metab, vol.18, pp.186-90, 2016. ,
LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial, Diabetes Care, vol.41, pp.1663-71, 2018. ,
Validation and validity of diagnoses in the General Practice Research Database: a systematic review, Br J Clin Pharmacol, vol.69, pp.4-14, 2010. ,
Validity of the general practice research database, Pharmacotherapy, vol.23, pp.686-695, 2003. ,
Clinical information for research; the use of general practice databases, J Public Health Med, vol.21, pp.299-304, 1999. ,
Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom, Epidemiology, vol.29, pp.308-321, 2018. ,
Cancer recording and mortality in the General Practice Research Database and linked cancer registries, Pharmacoepidemiol Drug Saf, vol.22, pp.168-75, 2013. ,
, See rights and reprints
Cancer recording in patients with and without type 2 diabetes in the Clinical Practice Research Datalink primary care data and linked hospital admission data: a cohort study, BMJ Open, vol.8, p.20827, 2018. ,
Validity of cancer diagnosis in a primary care database compared with linked cancer registrations in England. Population-based cohort study, Cancer Epidemiol, vol.36, pp.425-434, 2012. ,
Multiple Imputation for Nonresponse in Surveys, Wiley Series in Probability and Statistics, 1987. ,
Analysis of incomplete multivariate data, 1997. ,
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors, Clin Pharmacokinet, vol.51, pp.501-515, 2012. ,
, EMDAC Background document Victoza (liraglutide) -LEADER FDA Briefing Document, 2017.
A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, vol.94, pp.496-509, 1999. ,
Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics, Pharmacoepidemiol Drug Saf, vol.15, pp.291-303, 2006. ,
Negative controls: a tool for detecting confounding and bias in observational studies, Epidemiology, vol.21, pp.383-391, 2010. ,
, VigiBase: signalling harm and pointing to safer use Uppsala Monitoring Centre, 2017.
Alogliptin after acute coronary syndrome in patients with type 2 diabetes, EXAMINE Investigators, vol.369, pp.1327-1362, 2013. ,
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med, vol.373, pp.232-274, 2015. ,
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome, N Engl J Med, vol.373, pp.2247-57, 2015. ,
SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, vol.375, pp.1834-1878, 2016. ,
EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med, vol.377, pp.1228-1267, 2017. ,
SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N Engl J Med, vol.369, pp.1317-1343, 2013. ,
NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial, JAMA, vol.314, pp.687-99, 2015. ,
SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management, N Engl J Med, vol.373, pp.11-22, 2015. ,
Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide, Int J Obes (Lond), vol.36, pp.843-54, 2012. ,
, Lancet, vol.383, pp.2168-79, 2014.
Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus, JAMA Intern Med, vol.176, pp.1474-81, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01836887
Evaluating medication effects outside of clinical trials: new-user designs, Am J Epidemiol, vol.158, pp.915-935, 2003. ,
Immortal time bias in pharmaco-epidemiology, Am J Epidemiol, vol.167, pp.492-501, 2008. ,
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions, Pharmacoepidemiol Drug Saf, vol.11, pp.3-10, 2002. ,
Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study, BMJ Open, vol.6, p.10210, 2016. ,
Identification of incident pancreatic cancer in Ontario administrative health data: A validation study, Pharmacoepidemiol Drug Saf, 2018. ,
Risk factors for cholangiocarcinoma, Hepatology, vol.54, pp.173-84, 2011. ,